Disease-modifying therapies for transthyretin amyloidosis (ATTR) approved by the US Food and Drug Administration
| Drug | Indication | Effect on transthyretin |
|---|---|---|
| Tafamidis | Wild-type or hereditary ATTR cardiomyopathy | Stabilizer |
| Vutrisiran | Hereditary ATTR with neuropathy | Silencer |
| Patisiran | Hereditary ATTR with neuropathy | Silencer |
| Inotersen | Hereditary ATTR with neuropathy | Silencer |